Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles.

Templeton NS, Senzer N.

J Genet Syndr Gene Ther. 2011 Dec 17;(S5). pii: 002.

2.

PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform.

Liu SH, Rao DD, Nemunaitis J, Senzer N, Zhou G, Dawson D, Gingras MC, Wang Z, Gibbs R, Norman M, Templeton NS, Demayo FJ, O'Malley B, Sanchez R, Fisher WE, Brunicardi FC.

PLoS One. 2012;7(8):e40452. doi: 10.1371/journal.pone.0040452. Epub 2012 Aug 8.

3.

Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery.

Templeton NS, Senzer N.

J Drug Deliv. 2012;2012:173465. doi: 10.1155/2012/173465. Epub 2012 May 10.

4.

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA.

PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25.

5.

Oncolytic viruses for induction of anti-tumor immunity.

Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J.

Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60. Review.

PMID:
21740355
6.

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.

Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C, Kumar P, Pappen BO, Rao DD, Templeton NS, Daniels EQ, Webb C, Monsma D, Scott S, Dylewski D, Frieboes HB, Brunicardi FC, Senzer N, Maples PB, Nemunaitis J, Tong AW.

DNA Cell Biol. 2011 Sep;30(9):715-26. doi: 10.1089/dna.2011.1240. Epub 2011 May 25.

PMID:
21612405
7.

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.

Nemunaitis G, Jay CM, Maples PB, Gahl WA, Huizing M, Yardeni T, Tong AW, Phadke AP, Pappen BO, Bedell C, Allen H, Hernandez C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J.

Hum Gene Ther. 2011 Nov;22(11):1331-41. doi: 10.1089/hum.2010.192. Epub 2011 Apr 25.

8.

Liposomes for gene transfer in cancer therapy.

Templeton NS.

Methods Mol Biol. 2010;651:271-8. doi: 10.1007/978-1-60761-786-0_15.

PMID:
20686971
9.

Identification and removal of colanic acid from plasmid DNA preparations: implications for gene therapy.

Firozi P, Zhang W, Chen L, Quiocho FA, Worley KC, Templeton NS.

Gene Ther. 2010 Dec;17(12):1484-99. doi: 10.1038/gt.2010.97. Epub 2010 Jul 22.

10.

A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.

Shi Q, Nguyen AT, Angell Y, Deng D, Na CR, Burgess K, Roberts DD, Brunicardi FC, Templeton NS.

Gene Ther. 2010 Sep;17(9):1085-97. doi: 10.1038/gt.2010.55. Epub 2010 May 13.

11.

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy.

Nemunaitis G, Maples PB, Jay C, Gahl WA, Huizing M, Poling J, Tong AW, Phadke AP, Pappen BO, Bedell C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J.

J Gene Med. 2010 May;12(5):403-12. doi: 10.1002/jgm.1450.

PMID:
20440751
12.

Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2.

Phadke AP, Jay C, Chen SJ, Haddock C, Wang Z, Yu Y, Nemunaitis D, Nemunaitis G, Templeton NS, Senzer N, Maples PB, Tong AW, Nemunaitis J.

Gene Regul Syst Bio. 2009 May 8;3:89-101.

13.

Nonviral delivery for genomic therapy of cancer.

Templeton NS.

World J Surg. 2009 Apr;33(4):685-97. doi: 10.1007/s00268-008-9825-0. Review.

PMID:
19023615
14.

PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer.

Liu S, Ballian N, Belaguli NS, Patel S, Li M, Templeton NS, Gingras MC, Gibbs R, Fisher W, Brunicardi FC.

Pancreas. 2008 Aug;37(2):210-20. doi: 10.1097/MPA.0b013e31816a4a33.

PMID:
18665085
15.

Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

Mercier GT, Nehete PN, Passeri MF, Nehete BN, Weaver EA, Templeton NS, Schluns K, Buchl SS, Sastry KJ, Barry MA.

Vaccine. 2007 Dec 17;25(52):8687-701. Epub 2007 Nov 5.

16.
17.

Intravenous delivery of liposome-mediated nonviral DNA is less toxic than intraperitoneal delivery in mice.

Wang XP, Yazawa K, Templeton NS, Yang J, Liu S, Li Z, Li M, Yao Q, Chen C, Brunicardi FC.

World J Surg. 2005 Mar;29(3):339-43.

PMID:
15706434
18.

Cell-specific cytotoxicity of human pancreatic adenocarcinoma cells using rat insulin promoter thymidine kinase-directed gene therapy.

Tirone TA, Wang XP, Templeton NS, Lee T, Nguyen L, Fisher W, Brunicardi FC.

World J Surg. 2004 Aug;28(8):826-33. Epub 2004 Aug 3.

PMID:
15457366
19.

Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids.

Yotnda P, Davis AR, Hicks MJ, Templeton NS, Brenner MK.

Mol Ther. 2004 Apr;9(4):489-95. Erratum in: Mol Ther. 2004 Aug;10(2):404. Benner, MK [corrected to Brenner, MK].

20.

Optimization of gene expression in nonactivated circulating lymphocytes.

Zhang Y, Lu H, LiWang P, Sili U, Templeton NS.

Mol Ther. 2003 Oct;8(4):629-36.

21.

Modeling human breast cancer metastasis in mice: maspin as a paradigm.

Shi HY, Zhang W, Liang R, Kittrell F, Templeton NS, Medina D, Zhang M.

Histol Histopathol. 2003 Jan;18(1):201-6. doi: 10.14670/HH-18.201. Review.

PMID:
12507299
22.

Enhanced gene expression in breast cancer cells in vitro and tumors in vivo.

Lu H, Zhang Y, Roberts DD, Osborne CK, Templeton NS.

Mol Ther. 2002 Dec;6(6):783-92.

23.

Cationic liposome-mediated gene delivery in vivo.

Templeton NS.

Biosci Rep. 2002 Apr;22(2):283-95. Review.

PMID:
12428905
24.

Noninvasive imaging of cationic lipid-mediated delivery of optical and PET reporter genes in living mice.

Iyer M, Berenji M, Templeton NS, Gambhir SS.

Mol Ther. 2002 Oct;6(4):555-62.

25.
26.

Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation.

Barazi HO, Zhou L, Templeton NS, Krutzsch HC, Roberts DD.

Cancer Res. 2002 Mar 1;62(5):1541-8.

27.

Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses.

Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK.

Mol Ther. 2002 Mar;5(3):233-41.

28.

Developments in liposomal gene delivery systems.

Templeton NS.

Expert Opin Biol Ther. 2001 Jul;1(4):567-70. No abstract available.

PMID:
11727494
29.

Conformational regulation of the fibronectin binding and alpha 3beta 1 integrin-mediated adhesive activities of thrombospondin-1.

Rodrigues RG, Guo N, Zhou L, Sipes JM, Williams SB, Templeton NS, Gralnick HR, Roberts DD.

J Biol Chem. 2001 Jul 27;276(30):27913-22. Epub 2001 May 17.

30.

Insulinoma-induced hypoglycemic death in mice is prevented with beta cell-specific gene therapy.

Tirone TA, Fagan SP, Templeton NS, Wang X, Brunicardi FC.

Ann Surg. 2001 May;233(5):603-11.

31.

Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector.

Ramesh R, Saeki T, Templeton NS, Ji L, Stephens LC, Ito I, Wilson DR, Wu Z, Branch CD, Minna JD, Roth JA.

Mol Ther. 2001 Mar;3(3):337-50.

32.

Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells.

Guo N, Templeton NS, Al-Barazi H, Cashel JA, Sipes JM, Krutzsch HC, Roberts DD.

Cancer Res. 2000 Jan 15;60(2):457-66.

33.

Strategies for improving the frequency and assessment of homologous recombination.

Templeton NS.

Methods Mol Biol. 2000;133:45-60. No abstract available.

PMID:
10561830
34.

New directions in liposome gene delivery.

Templeton NS, Lasic DD.

Mol Biotechnol. 1999 Apr;11(2):175-80. Review.

PMID:
10464771
35.

Efficient gene targeting in mouse embryonic stem cells.

Templeton NS, Roberts DD, Safer B.

Gene Ther. 1997 Jul;4(7):700-9.

36.

Improved DNA: liposome complexes for increased systemic delivery and gene expression.

Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN.

Nat Biotechnol. 1997 Jul;15(7):647-52.

PMID:
9219267
37.
38.

Reducing artifact and increasing the yield of specific DNA target fragments during PCR-RACE or anchor PCR.

Templeton NS, Urcelay E, Safer B.

Biotechniques. 1993 Jul;15(1):48-50, 52. No abstract available.

PMID:
8363838
39.

The polymerase chain reaction. History, methods, and applications.

Templeton NS.

Diagn Mol Pathol. 1992 Mar;1(1):58-72.

PMID:
1342955
40.

Cloning and characterization of a novel human cDNA that has DNA similarity to the conserved region of the collagenase gene family.

Templeton NS, Rodgers LA, Levy AT, Ting KL, Krutzsch HC, Liotta LA, Stetler-Stevenson WG.

Genomics. 1992 Jan;12(1):175-6. No abstract available.

PMID:
1310294
42.

Cloning and characterization of human tumor cell interstitial collagenase.

Templeton NS, Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG.

Cancer Res. 1990 Sep 1;50(17):5431-7.

43.

Selective expression of alternative lck mRNAs in human malignant cell lines.

Sartor O, Gregory FS, Templeton NS, Pawar S, Perlmutter RM, Rosen N.

Mol Cell Biol. 1989 Jul;9(7):2983-8.

44.
45.

Cleavage of the site-specific recombination protein gamma delta resolvase: the smaller of two fragments binds DNA specifically.

Abdel-Meguid SS, Grindley ND, Templeton NS, Steitz TA.

Proc Natl Acad Sci U S A. 1984 Apr;81(7):2001-5.

Supplemental Content

Loading ...
Support Center